Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model

Yan-hong Zhang; Ying Zhang; Jing Li; Wen-xin Tong; Feng-qin Xu

doi:10.1007/s11655-015-2298-8

Your Location：

Home >

Browse articles >

Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model

Updated：2021-08-27

- Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model
- Chinese Journal of Integrative Medicine Vol. 23, Issue 5, Pages: 357-361(2017)
- Affiliations：
  
  1. Department of Emergency, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  2. Department of General Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  3. Administration Office, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81173385)
- DOI：10.1007/s11655-015-2298-8
  CLC：
- Published：2017，
  
  Published Online：10 October 2015，
Scan for full text
Zhang, Yh., Zhang, Y., Li, J. et al. Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model., Chin. J. Integr. Med. 23, 357–361 (2017). https://doi.org/10.1007/s11655-015-2298-8

Yan-hong Zhang, Ying Zhang, Jing Li, et al. Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model. [J]. Chinese Journal of Integrative Medicine 23(5):357-361(2017)
Zhang, Yh., Zhang, Y., Li, J. et al. Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model., Chin. J. Integr. Med. 23, 357–361 (2017). https://doi.org/10.1007/s11655-015-2298-8 DOI：

Yan-hong Zhang, Ying Zhang, Jing Li, et al. Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model. [J]. Chinese Journal of Integrative Medicine 23(5):357-361(2017) DOI： 10.1007/s11655-015-2298-8.

摘要

To observe the effects of Xiongshao Capsule (芎芍胶囊

XSC) on anti-inflflammatory properties of high-density lipoprotein (HDL)

myeloperoxidase (MPO) and paraoxonase 1 (PON1) in serum of atherosclerosis (AS) rabbit model and explore the anti-inflflammatory protective effects of XSC on HDL. Sixty rabbits were randomized into the control

the model

XSC low-

medium- and high-dose (Rhizoma Chuanxiong + Radix Paeoniae rubra: 0.6+0.3

1.2+0.6

2.4+1.2g·kg-1·day-1

respectively)

and simvastatin (1g·kg-1·day-1) groups. The model rabbits were fed with high-fat diet and drugs for 15 weeks. The blood and thoracic aortas samples were collected at the end of 15 weeks. The levels of serum MPO and PON1 as well as total cholesterol (TC) and free cholesterol (FC) in aorta wall cells were tested by enzyme linked immunosorbent assay. TC and FC in the model group were significantly higher than those in the control group (P<0.01). Compared with the model group

TC and FC in the XSC groups were signifificantly lower (P<0.05 or P<0.01)

so was simvastatin group (P<0.01). There was no signifificant difference in PON1 level between groups (P>0.05)

even between model and control groups (P>0.05). The serum MPO level in the model group was signifificantly higher than that in the control group (P<0.05)

which was signifificantly lower in XSC groups as well as simvastatin group (P<0.05 or P<0.01)

and no difference was found between XSC groups and simvastatin group (P>0.05). XSC can reduce the serum MPO level in AS rabbits to protect the anti-inflammatory function of HDL

maintaining the normal lipid transport function. TC and FC levels in aorta cells decline

and this process initiated by XSC plays an anti-AS role.

Abstract

To observe the effects of Xiongshao Capsule (芎芍胶囊

XSC) on anti-inflflammatory properties of high-density lipoprotein (HDL)

the model

XSC low-

medium- and high-dose (Rhizoma Chuanxiong + Radix Paeoniae rubra: 0.6+0.3

1.2+0.6

2.4+1.2g·kg-1·day-1

respectively)

TC and FC in the XSC groups were signifificantly lower (P<0.05 or P<0.01)

so was simvastatin group (P<0.01). There was no signifificant difference in PON1 level between groups (P>0.05)

even between model and control groups (P>0.05). The serum MPO level in the model group was signifificantly higher than that in the control group (P<0.05)

which was signifificantly lower in XSC groups as well as simvastatin group (P<0.05 or P<0.01)

and no difference was found between XSC groups and simvastatin group (P>0.05). XSC can reduce the serum MPO level in AS rabbits to protect the anti-inflammatory function of HDL

maintaining the normal lipid transport function. TC and FC levels in aorta cells decline

and this process initiated by XSC plays an anti-AS role.

关键词

blood-activating and stasis-dissolvinganti-atherosclerosisanti-inflammatoryfunctional high density lipoproteinChinese Medicine

Keywords

blood-activating and stasis-dissolvinganti-atherosclerosisanti-inflammatoryfunctional high density lipoproteinChinese Medicine

references

Verdier C, Martinez LO, Ferrières J, Elbaz M, Genoux A, Perret B. Targeting high-density lipoproteins: update on a promising therapy. Arch Cardiovasc Dis 2013;106:601–611.

Sorci-Thomas MG, Thomas MJ. Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol 2013;62:239–246.

Alwaili K, Awan Z, Alshahrani A, Genest J. High-density lipoproteins and cardio-vascular disease: 2010 update. Expert Rev Cardiovasc Ther 2010;8:413–423.

De la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012;222:390–394.

Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol 2005;46:1792–1798.

Kotosai M, Shimada S, Kanda M, Matsuda N, Sekido K, Shimizu Y, et al. Plasma HDL reduces non-esterified fatty acid hydroperoxides originating from oxidized LDL: a mechanism for its antioxidant ability. Lipids 2013;48:569–578.

Li LZ, Liu JG, Ma LB, Lu XY, Xu H, Xu FQ, et al. Effect of Xiongshao Capsule on lipid metabolism and platelet aggregation in experimental atherosclerosis rabbits. Chin J Integr Tradit West Med (Chin) 2008;28:1100–1103.

Barter P. Lessons learned from the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Am J Cardiol 2009;104(10 Suppl):10E–5E.

Triolo M, Annema W, Dullaart RP, Tietge UJ. Assessing the functional properties of high density lipoproteins: an emerging concept in cardiovascular research. Biomark Med 2013;7:457–472.

Wu JX, Liang C, Wu ZG. The functions of HDL and related research progress on atherosclerosis. Shanghai Med J (Chin) 2010;33:1062–1066.

Fuhrman B, Gantman A, Aviram M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 2010;211:61–68.

Eren E, Yilmaz N, Aydin O. Functionally defective highdensity lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis. Cholesterol 2013;2013:792090.

Zhou QY. The correlation between serum paraoxonase-1 level and types of acute coronary syndrome. Chin Gener Pract Chin 2013;16:3189–3191.

Zhou C, Cao J, Shang L, Tong C, Hu H, Wang H, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis Markers 2013;35:97–103.

Hewing B, Parathath S, Barrett T, Chung WK, Astudillo YM, Hamada T, et al. Effects of native and myeloperoxidase modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2014;34:779–789.

Shao B, Tang C, Sinha A, Mayer PS, Davenport G, Brot N, et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced HDL oxidation by myeloperoxidase. Circ Res 2014;114:1733–1742.

Sokolov AV, Kostevich VA, Runova OL, Gorudko IV, Vasilyev VB, Cherenkevich SN, et al. Proatherogenic modification of LDL by surface bound myeloperoxidase. Chem Phys Lipids 2014;180:72–80.

Delporte C, Van Antwerpen P, Vanhamme L, Roumeguère T, Zouaoui Boudjeltia K. Low-density lipoprotein modifyed by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm 2013;2013:971579.

Rudolph TK, Schaper N, Klinke A, Demir C, Goldmann B, Lau D, et al. Liberation of vessel adherent myeloperoxidase reflects plaque burden in patients with stable coronary artery disease. Atherosclerosis 2013;231:354–358.

Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123:3815–3828.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Anti-inflammatory and immunoregulatory effects of Yupingfeng (玉屏风) powder on chronic bronchitis rats

Review of Anemone raddeana Rhizome and its pharmacological effects

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Related Author

No data

Related Institution

School of Pharmacy, Anhui Medical University

Medical College, Hangzhou Normal University

Suzhou Dongrui Pharmaceutical Co., Ltd.

Traditional Chinese Medicine College, Guangdong Pharmaceutical University

Department of Acupucture, Hangzhou Traditional Chinese Medicine Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰